首页> 外文期刊>Clinical rheumatology >Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study
【24h】

Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study

机译:结缔组织病患者血清KL-6水平与间质性肺疾病的关联:一项横断面研究

获取原文
获取原文并翻译 | 示例
           

摘要

It was aimed to evaluate KL-6 glycoprotein levels to determine if it may be a diagnostic marker for the connective tissue diseases (CTDs) predicting CTD-related interstitial lung diseases (ILDs) (CTD-ILD) development and to examine if there was a difference between patients and healthy controls. The study included 113 patients with CTD (45 CTD without lung involvement, 68 CTD-ILD) and 45 healthy control subjects. KL-6 glycoprotein levels were analyzed with ELISA in patients and the control group. The relationship between KL-6 glycoprotein levels and CTD-ILD was assessed. In the comparison of all the groups in the study, significantly higher levels of KL-6 were determined in the CTD-ILD group than in either the CTD without pulmonary involvement group or the healthy control group (p < 0.008 and p < 0.001, respectively). There was no statistically significant difference between the KL-6 levels in the healthy control group and the CTD without pulmonary involvement group (p = 0.289). The KL-6 levels did not differ significantly according to the connective tissue diseases in the diagnostic groups (systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, mixed connective tissue disease, scleroderma, polymyositis/ dermatomyositis). In the healthy control group, there was a statistically significant difference between KL-6 levels in smokers and non-smokers. Smokers had significantly higher serum KL-6 levels compared with non-smokers (p < 0.05). There was no statistically significant difference between smoking status (pack-year) and serum KL-6 levels. There was no statistically significant correlation between serum KL-6 levels and time since diagnosis of CTD and CTD-ILD. The level of KL-6 as a predictive factor could be used to identify the clinical development of ILD before it is detected on imaging modality. Further prospective clinical studies are needed to define whether levels of KL-6 might have prognostic value or might predict progressive ILD.
机译:目的是评估KL-6糖蛋白水平,以确定它是否可能是预测CTD相关性间质性肺病(ILD)(CTD-ILD)发展的结缔组织疾病(CTD)的诊断标志,并检查是否存在患者与健康对照之间的差异。该研究包括113名CTD患者(45名无肺部CTD,68名CTD-ILD)和45名健康对照组。用ELISA法分析了患者和对照组的KL-6糖蛋白水平。评估了KL-6糖蛋白水平与CTD-ILD之间的关系。在研究中所有组的比较中,CTD-ILD组中确定的KL-6水平明显高于没有肺部受累组的CTD或健康对照组(分别为p <0.008和p <0.001) )。在健康对照组和没有肺部受累组的CTD中,KL-6水平之间无统计学差异(p = 0.289)。诊断组的结缔组织疾病(系统性红斑狼疮,干燥综合征,类风湿性关节炎,混合性结缔组织病,硬皮病,多发性肌炎/皮肌炎)的KL-6水平没有显着差异。在健康对照组中,吸烟者和非吸烟者的KL-6水平之间存在统计学差异。与不吸烟者相比,吸烟者血清KL-6水平显着更高(p <0.05)。吸烟状态(每包年)与血清KL-6水平之间无统计学差异。自诊断出CTD和CTD-ILD以来,血清KL-6水平与时间之间无统计学意义的相关性。 KL-6的水平作为预测因素可用于在影像学手段上检测到ILD之前确定其临床发展。需要进一步的前瞻性临床研究来确定KL-6水平是否可能具有预后价值或可以预测进行性ILD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号